Mitigating ipatasertib‐induced glucose increase through dose and meal timing modifications

Abstract Ipatasertib, an AKT inhibitor, in combination with prednisone and abiraterone, is under evaluation for the treatment of metastatic castration‐resistant prostate cancer (mCRPC). Hyperglycemia is an on‐target effect of ipatasertib. An open‐label, single‐arm, single‐sequence, signal‐seeking st...

Full description

Bibliographic Details

Published in:	Clinical and Translational Science
Main Authors:	Dhruvitkumar S. Sutaria, Priya Agarwal, Kuan‐Chieh Huang, Dale R. Miles, Jacob Rotmensch, Heather Hinton, Jorge Daniel Gallo, Grozdana Rasuo, Rucha S. Sane
Format:	Article
Language:	English
Published:	Wiley 2022-12-01
Online Access:	https://doi.org/10.1111/cts.13420